The effects of oral hydrolytic enzymes and flavonoids on inflammatory markers and coagulation after marathon running: study protocol for a randomized, double-blind, placebo-controlled trial
Tóm tắt
Regular moderate intensity physical activity positively influences the immune system with a lower incidence of upper respiratory tract infections (URTI) and lower levels of pro-inflammatory markers. However, marathon running due to its strenuous and prolonged nature results in immune perturbations with a major increase in pro-inflammatory markers and subsequent increased incidence of URTI. Furthermore, marathon running results in muscle damage and changes in hemostasis that promote a pro-thrombotic state. Naturally occurring hydrolytic enzymes and flavonoids have antioxidant, anti-inflammatory and fibrinolytic effects, and may serve as countermeasures to exercise-induced inflammation, immune dysfunction and URTI. The aim of this study is to determine whether the ingestion of oral hydrolytic enzymes and flavonoids before and after a marathon attenuates post-race muscle damage and inflammation, counters pro-thrombotic changes in hemostasis and decreases URTI incidence. The Enzy-MagIC-study (Enzymes, Marathon runninG, Inflammation, Coagulation) is a randomized, double-blind, placebo-controlled, monocenter phase I trial. 160 healthy males (age 20-65 years) will be randomized to receive either placebo or treatment (Wobenzym, MUCOS Pharma, Berlin, Germany) which contains the hydrolytic enzymes (bromelain, trypsin) and the flavonoid rutoside. One week before the marathon race, participants will begin daily ingestion of the investigational product (3×4 tablets). Intake will be continued for two weeks after the race (3×2 tablets per day). Clinical and laboratory measures will be collected 5-weeks and 1-week before the race, and immediately-, 24-h, 72-h, and 2 weeks after the race. The primary endpoint is the influence of the treatment on the pre-to-post marathon race plasma concentration change of the inflammatory marker interleukin-6 (IL-6). Secondary endpoints include the effect of treatment on salivary IgA concentration and the frequency of upper respiratory tract infections (URTI) for two weeks post-marathon as determined by the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Furthermore, changes of muscular and rheological parameters will be measured before and after the marathon race. We hypothesize that marathon-induced inflammatory perturbations and the incidence of subsequent URTI, muscular damage, and changes of hemostasis can be positively influenced by the anti-edematous, anti-inflammatory, antioxidant, and fibrinolytic effects of oral hydrolytic enzymes and flavonoids (Wobenzym). ClinicalTrials.gov Identifier:
NCT01916408
Tài liệu tham khảo
Mathur N, Pedersen BK: Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm. 2008, 2008: 109502.
Petersen AM, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol. 2005, 98: 1154-1162. 10.1152/japplphysiol.00164.2004.
Chubak J, McTiernan A, Sorensen B, Wener MH, Yasui Y, Velasquez M, Wood B, Rajan KB, Wetmore CM, Potter JD, Ulrich CM: Moderate-intensity exercise reduces the incidence of colds among postmenopausal women. Am J Med. 2006, 119: 937-942. 10.1016/j.amjmed.2006.06.033.
Ekblom B, Ekblom O, Malm C: Infectious episodes before and after a marathon race. Scand J Med Sci Sports. 2006, 16: 287-293. 10.1111/j.1600-0838.2005.00490.x.
Nieman DC: Risk of upper respiratory tract infection in athletes: an epidemiologic and immunologic perspective. J Athl Train. 1997, 32: 344-349.
Scherr J, Nieman DC, Schuster T, Habermann J, Rank M, Braun S, Pressler A, Wolfarth B, Halle M: Non-alcoholic beer reduces inflammation and incidence of respiratory tract illness. Med Sci Sports Exerc. 2012, 44: 8-26.
Nieman DC, Henson DA, Smith LL, Utter AC, Vinci DM, Davis JM, Kaminsky DE, Shute M: Cytokine changes after a marathon race. J Appl Physiol. 2001, 91: 109-114.
Ostrowski K, Schjerling P, Pedersen BK: Physical activity and plasma interleukin-6 in humans–effect of intensity of exercise. Eur J Appl Physiol. 2000, 83: 512-515. 10.1007/s004210000312.
Akira S, Taga T, Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol. 1993, 54: 1-78.
Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J. 1990, 265: 621-636.
Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation. 2002, 105: 1135-1143. 10.1161/hc0902.104353.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001, 286: 327-334. 10.1001/jama.286.3.327.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000, 101: 1767-1772. 10.1161/01.CIR.101.15.1767.
Empana JP, Jouven X, Canouï-Poitrine F, Luc G, Tafflet M, Haas B, Arveiler D, Ferrieres J, Ruidavets JB, Montaye M, Yarnell J, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P: C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arterioscler Thromb Vasc Biol. 2010, 30: 2047-2052. 10.1161/ATVBAHA.110.208785.
Stouthard JM, Levi M, Hack CE, Veenhof CH, Romijn HA, Sauerwein HP, van der Poll T: Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost. 1996, 76: 738-742.
Jones SA: Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol. 2005, 175: 3463-3468.
Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK: Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol. 1999, 515 (Pt 1): 287-291.
Pedersen BK, Febbraio MA: Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008, 88: 1379-1406. 10.1152/physrev.90100.2007.
Kratz A, Lewandrowski KB, Siegel AJ, Chun KY, Flood JG, Van Cott EM, Lee-Lewandrowski E: Effect of marathon running on hematologic and biochemical laboratory parameters, including cardiac markers. Am J Clin Pathol. 2002, 118: 856-863. 10.1309/14TY-2TDJ-1X0Y-1V6V.
Smith JE: Effects of strenuous exercise on haemostasis. Br J Sports Med. 2003, 37: 433-435. 10.1136/bjsm.37.5.433.
Kuo SM: Dietary flavonoid and cancer prevention: evidence and potential mechanism. Crit Rev Oncog. 1997, 8: 47-69. 10.1615/CritRevOncog.v8.i1.30.
Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, Whelton PK: Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first national health and nutrition examination survey epidemiologic follow-up study. Am J Clin Nutr. 2002, 76: 93-99.
Lotito SB, Frei B: Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?. Free Radic Biol Med. 2006, 41: 1727-1746. 10.1016/j.freeradbiomed.2006.04.033.
Heinonen M: Antioxidant activity and antimicrobial effect of berry phenolics–a Finnish perspective. Mol Nutr Food Res. 2007, 51: 684-691. 10.1002/mnfr.200700006.
Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP: Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol. 2008, 128: 66-74. 10.1016/j.clim.2008.02.015.
Manach C, Morand C, Demigne C, Texier O, Regerat F, Remesy C: Bioavailability of rutin and quercetin in rats. FEBS Lett. 1997, 409: 12-16. 10.1016/S0014-5793(97)00467-5.
Nieman DC, Henson DA, Gross SJ, Jenkins DP, Davis JM, Murphy EA, Carmichael MD, Dumke CL, Utter AC, McAnulty SR, McAnulty LS, Mayer EP: Quercetin reduces illness but not immune perturbations after intensive exercise. Med Sci Sports Exerc. 2007, 39: 1561-1569. 10.1249/mss.0b013e318076b566.
Nieman DC, Henson DA, Maxwell KR, Williams AS, McAnulty SR, Jin F, Shanely RA, Lines TC: Effects of quercetin and EGCG on mitochondrial biogenesis and immunity. Med Sci Sports Exerc. 2009, 41: 1467-1475. 10.1249/MSS.0b013e318199491f.
Huang RY, Yu YL, CHeng WC, OuYang CN, Fu E, Chu CL: Immunosuppressive effect of quercetin on dendritic cell activation and function. J Immunol. 2010, 184: 6815-6821. 10.4049/jimmunol.0903991.
Nilsson J, Pillai D, Onning G, Persson C, Nilsson A, Akesson B: Comparison of the 2,2′-azinobis-3-ethylbenzotiazo-line-6-sulfonic acid (ABTS) and ferric reducing anti-oxidant power (FRAP) methods to asses the total antioxidant capacity in extracts of fruit and vegetables. Mol Nutr Food Res. 2005, 49: 239-246. 10.1002/mnfr.200400083.
Maurer HR: Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci. 2001, 58: 1234-1245. 10.1007/PL00000936.
Nieman DC: Immunonutrition support for athletes. Nutr Rev. 2008, 66: 310-320. 10.1111/j.1753-4887.2008.00038.x.
Braun JM, Schneider B, Beuth HJ: Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany. In Vivo. 2005, 19: 417-421.
Klein G, Kullich W, Schnitker J, Schwann H: Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006, 24: 25-30.
Onken JE, Greer PK, Calingaert B, Hale LP: Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies. In Vitro Clin Immunol. 2008, 126: 345-352. 10.1016/j.clim.2007.11.002.
Neumayer C, Fugl A, Nanobashvili J, Blumer R, Punz A, Gruber H, Polterauer P, Huk I: Combined enzymatic and antioxidative treatment reduces ischemia-reperfusion injury in rabbit skeletal muscle. J Surg Res. 2006, 133: 150-158. 10.1016/j.jss.2005.12.005.
Reed CE, Kita H: The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol. 2004, 114: 997-1008. 10.1016/j.jaci.2004.07.060.
McLean PG, Aston D, Sarkar D, Ahluwalia A: Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res. 2002, 90: 465-472. 10.1161/hh0402.105372.
Wittenborg A, Bock PR, Hanisch J, Saller R, Schneider B: [Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti- inflammatory drugs versus an oral enzyme combination preparation]. Arzneimittelforschung. 2000, 50: 728-738.
Gaciong Z, Paczek L, Bojakowski K, Socha K, Wisniewski M, Heidland A: Beneficial effect of proteases on allograft arteriosclerosis in a rat aortic model. Nephrol Dial Transplant. 1996, 11: 987-989. 10.1093/oxfordjournals.ndt.a027521.
WHO definition of health. [http://www.who.int/healthsystems/hss_glossary/en/index5.html].
Roots I: Bioverfügbarkeit von Trypsin, Bromelain und Rutoside-Metaboliten nach oraler Gabe von Phlogenzym® bei gesunden Probanden. Randomisierte doppelblinde crossovere-Studie. Final report. 1997, Institute for Clinical Pharmacology, Humboldt University Berlin
Melzack R: The short-form McGill pain questionnaire. Pain. 1987, 30: 191-197. 10.1016/0304-3959(87)91074-8.
Barrett B, Brown RL, Mundt MP, Thomas GR, Barlow SK, Highstrom AD, Bahrainian M: Validation of a short form Wisconsin Upper Respiratory Symptom Survey (WURSS-21). Health Qual Life Outcomes. 2009, 7: 76-10.1186/1477-7525-7-76.
Scherr J, Braun S, Schuster T, Hartmann C, Moehlenkamp S, Wolfarth B, Pressler A, Halle M: 72-h kinetics of high-sensitive troponin T and inflammatory markers after marathon. Med Sci Sports Exerc. 2011, 43: 1819-1827. 10.1249/MSS.0b013e31821b12eb.
Pagonis C, Tauber AI, Pavlotsky N, Simons ER: Flavonoid impairment of neutrophil response. Biochem Pharmacol. 1986, 35: 237-245. 10.1016/0006-2952(86)90520-4.
Ravikumar T, Ramakrishnan M, Jayaraman V, Babu M: Effect of trypsin-chymotrypsin (Chymoral Forte D.S.) preparation on the modulation of cytokine levels in burn patients. Burns. 2001, 27: 709-716. 10.1016/S0305-4179(01)00037-7.
Akhtar NM, Naseer R, Farooqi AZ, Aziz W, Nazir M: Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee–a double-blind prospective randomized study. Clin Rheumatol. 2004, 23: 410-415. 10.1007/s10067-004-0902-y.
Metzig C, Grabowska E, Eckert K, Rehse K, Maurer HR: Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo. 1999, 13: 7-12.
Livio M, Bertoni MP, DeGaetano G: Effect of bromelain on fibrinogen level, prothrombin complex factors and platelet aggregation in the rat - a preliminary report. Drugs Expt Clin Res. 1978, 4: 49-53.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/2052-1847/6/8/prepub